



# **North American Brain Injury Society's 18th Annual Conference on Brain Injury: Advancing Evidence Informed Clinical Care, Rehabilitation Outcomes and Lifelong Living**

**Live In-person  
Arlington, VA  
March 11 – 13, 2026**

## **Continuing Education Information**

This continuing education activity is provided by AffinityCE and the North American Brain Injury Society (NABIS). This activity provides continuing education credit for physicians, nurses, psychologists, social workers, occupational therapists, physical therapists, rehabilitation counselors, case managers, and speech language professionals. A statement of participation is available to other attendees.

## **Description**

Participants will review the current evidence-based guidelines and neurocritical care principles associated with the acute clinical assessment and management of patients with severe brain injury, including medical and rehabilitation considerations, strategies that help support research to address the causes, consequences of brain injury, prevention methodologies, effective treatment interventions and case management approaches that can support rehabilitation programs in both educational and school settings.

**Course Registration Link:** <https://ibia.wildapricot.org/event-6256211/Registration>

## **Learning Objectives**

At the end of this activity, participants should be able to:

- Describe current evidence-based guidelines and neurocritical care principles for the acute clinical assessment and management of patients with severe brain injury, including medical and rehabilitation considerations.
- Describe how to implement clinically relevant approaches to acute assessment, autonomic screening, pediatric-specific issues, and efficient use of new office evaluation tools for concussion/mTBI.
- Describe specific issues for return to sport for youth, adult, and masters-level athletes.

- Describe the scope of autonomic dysfunction after mild and severe TBI.
- implement best-evidence recommendations regarding return to work, school, and physical activity after concussion.
- Design actionable plans to promote advocacy, interdisciplinary education, and translational research that address the full continuum of brain injury—from disorders of consciousness to chronic care and lifelong support.

### **Disclosures**

AffinityCE staff, NABIS staff, as well as planners and reviewers have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures will be available for participant viewing prior to engagement with program content.

### **Faculty Disclosures**

#### **Dr. David Arciniegas, M.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

#### **Dr Yelena G. Bodien, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

#### **Dr. Lisa Brenner, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

#### **Dr. Meeryo Christa Choe, MD, FAAN**

- Cognify: Chief Medical Officer/Consultant
- No discussion of unapproved drug or product uses

#### **Dr. John D. Corrigan, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

#### **Dr Carrie Esopenko, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Steven Flanagan, M.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Joseph T Giacino, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Gerard Gioia, Ph.D.**

- Psychological Assessment Resources, Inc.: Test Author
- No discussion of unapproved drug or product uses

**Dr. Christopher C Giza, M.D.**

- Medical Network Speakers Bureau: Speaker
- MLS, NBA: Advisory board (uncompensated)
- NBA, NFL, NHL/NHLPA, Los Angeles Lakers, Los Angeles Chargers: Clinical consultant (provide clinical care to athletes)
- Symptomwise: Company co-founder
- UCLA Brain Injury Research Center, US Dept of Defense, NINDS: Research grants
- UCLA Steve Tisch BrainSPORT Program, Easton Clinic for Brain Health: Philanthropic program support
- No discussion of unapproved drug or product uses

**Dr. Brian D Greenwald, MD**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Flora Hammond, M.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Sidney Hinds, II, MD, FAAN, COL (retired)**

- 2508 Biosciences: Advisory Board Member
- Ceresant Solutions: Advisory Board Member
- Concussion Legacy Foundation: Veteran Advisory Board Member
- CONNECT-TBi: Advisory Board Member
- Gryphon Bio: Advisory Board Member
- LIMBIC-CENC: Co-PI
- Major League Soccer Players Association: Medical Director

- NanoDX: Advisory Board Member
- National Football League Players Association: Former Deputy Medical Director and Chief Health Equity Officers
- Owl Therapeutics: Advisory Board Member
- Prevent Biometrics: Advisory Board Member
- TRANSFORM-TBI: Advisory Board Member
- University of Michigan Concussion Center: Advisory Board Member
- SCS Consulting LLC, Consultant and Owner (This company is a consulting company and does not produce/manufacture medical devices or technology.)
- No discussion of unapproved drug or product uses

**Dr. Ronald Hirschberg, M.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Ryan Holliday, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Tamerah N. Hunt, Ph.D., ATC**

- National Institute on Disability and Rehabilitation Research (NIDRR): Grant Reviewer
- SLACK Inc.: Author
- No discussion of unapproved drug or product uses

**Professor Grant L. Iverson, Ph.D.**

- Highmark, Inc: Consulting
- NanoDx: Consulting
- NeuroHealth Research and Rehabilitation, Inc.: Consulting
- NeuroHealth LLC, Sway Operations, LLC: Consulting
- No discussion of unapproved drug or product uses

**Dr. Anthony E Kline, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. John Leddy, M.D.**

- Zeiss: Consultant
- Minority owner interest in 360 Concussion Care
- Neck Care: Scientific Advisory Board
- No discussion of unapproved drug or product uses

**Professor Jonathan Lifshitz, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Brent E Masel, MD**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Ms. René Mills, M.S., CCC-SLP, CBIST**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Prof. Martin M Monti, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- Unapproved drug or product uses: Saxagliptin - for promoting recovery after severe brain injury

**Dr Dawn Neumann, Ph.D., FACRM**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Gregory J. O'Shanick, MD**

- Center for Neurorehabilitation Services: Owner
- President, Center for Neurorehabilitation Services
- No discussion of unapproved drug or product uses

**Dr. Matthew E. Peters, M.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Nick Reed, PhD, MSc.OT, OT Reg (Ont)**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Ronald C Savage, Ed.D**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Caroline Schnakers, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Ms. Heidi L Schneider, CNRN**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Beth Slomine, Ph.D.**

- Cambridge University Press: Book Editor
- No discussion of unapproved drug or product uses

**Captain Katherine Price Snedaker, LCSW**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Professor Leanne Togher, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Eve M. Valera, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Alan Weintraub, M.D, FACRM, FAAPMR**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Mr. Rick (Rick Willis & John Willis)**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Mrs. Rebecca Wolfkiel, MPP**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Nathan David Zasler, MD**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- Unapproved drug or product uses: May discuss off label use of neuromodulation devices for pain

**Dr. Roger Zemek, M.D., FRCPC**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Ms. Stephanie Ablner, M.S., CCC-SLP, CBIS**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Mrs. Michelle Baker, BS, RN-WCCM- CRRN, CCM**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Prof Steven P Broglio, Ph.D., ATC**

- Biomechanics of Injury (3rd edition, Human Kinetics): Author
- Brain Metabolism Monitoring Through CCO Measurements Using All-Fiber-Integrated Super-Continuum Source" (U.S. US 11, 529, 091 B2) and "Organ or Tissue Hemodynamic and Metabolic Function Measured Using Super-Continuum Light Sources" (US 12,089,945 B2): patent holder
- C3 Logix: Advisory Board
- No discussion of unapproved drug or product uses

**Dr. Haley M Chizuk, Ph.D., ATC**

- Carl ZEISS Meditec: Scientific Consultant
- No discussion of unapproved drug or product uses

**Ms. Britta NICOLE Colombo, M.S., CCC-SLP, CBIS**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Daniel J Corwin, MD, MSCE**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Kristen Dams-O'Connor, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Jennifer Dawson, MSc, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr Andrew Cullen Dennison, Sr, MD**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- Unapproved drug or product uses: Non-FDA labeled medications in the treatment of Brain Injury, DOC, and paroxysmal sympathetic hyperactivity.

**Dr. Ramon Diaz-Arrastia, MD, Ph.D.**

- Abbott: Research support to my institution
- No discussion of unapproved drug or product uses

**Dr. David Fischer, M.D.**

- Alpha sights: Consulting
- Atheneum: Consulting
- Becton Dickinson: Speaker fee
- No discussion of unapproved drug or product uses

**Dr. Kim Frey, PhD, CCC-SLP, CBIS**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Ms. Trisha Funk, MS, CCC-SLP**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Madison Harris, OTD, MA, OTR/L**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr Amelia Maiga, MD, MPH, FACS**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Geoffrey T. Manley, MD, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Brooke Marie Murtaugh, OTD, OTR/L, CBIST, BT-C**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Ms. Katherine A. O'Brien, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Shanti M Pinto, M.D., MSCS**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Vani Rao, MD**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- Unapproved drug or product uses: Because there are no FDA approved medications for the treatment of many of the psychiatric problems after TBI

**Dr. Amy Shapiro-Rosenbaum, Ph.D., ABPP**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Jeffrey Snell, Ph.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Candace Tefertiller, DPT, Ph.D.**

- Onward Medical: Educational Consultant
- No discussion of unapproved drug or product uses

**Dr. Jennifer A Weaver, PhD, OTR/L**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Ms. Danita Williams, R.N.-WCCM, BS, MBA, CCM**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Jean Woo, M.D.**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Dr. Keith Owen Yeates, Ph.D., ABPP, FCAHS, FRSC**

- No relevant financial relationships with ineligible companies associated with the content of this activity to disclose
- No discussion of unapproved drug or product uses

**Mitigation of Relevant Financial Relationships**

AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities. All relevant financial relationships reported have been mitigated.

**Physicians**



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and NABIS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of up to 18.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Occupational Therapists



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and NABIS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of up to 18.5 *AMA PRA Category 1 Credits™*. Occupational Therapists should claim only the credit commensurate with the extent of their participation in the activity.

## Nurses



Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NABIS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of up to 18.5 contact hours of continuing nursing education credit.

## Criterion for Claiming CNE Credit

Participants must have registered for the activity and fully attended all sessions for which credit will be claimed. Participants must also complete the activity evaluation for each session attended via the CE center.

## Physical Therapists



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and NABIS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of up to 18.5 *AMA PRA Category 1 Credits™*. Physical Therapists should claim only the credit commensurate with the extent of their participation in the activity.

## Psychologists

AffinityCE is approved by the American Psychological Association to sponsor continuing education for psychologists. AffinityCE maintains responsibility for this program and its content.

This activity provides up to 18.5 hours of CE Credit.

The instructional level of this activity is intermediate. The cost to participate in these CE sessions is included in the registration cost for the Program.

**Evaluation:** Psychologist participants are encouraged complete session evaluation forms, although it is not a requirement to receive CE credit. Attendance for Psychologist specific sessions is monitored via sign in, sign out and monitoring of active participation during the conference.

## Speech-Language Professionals



**ASHA CE**  
**APPROVED PROVIDER**

**AffinityCE**

Intermediate Level

Up to 1.85 ASHA CEUs

At the end of this activity, speech-language professionals (SLP) should be able to:

1. Describe the neuroanatomy of aphasia in TBI, especially considering dorsal and ventral tracts.
2. Describe the critical link between impaired social cognition after brain injury (BI) and adverse long-term outcomes.
3. Review the best-evidence recommendations regarding return to work, school, and physical activity after concussion.
4. Design actionable plans to promote advocacy, interdisciplinary education, and translational research that address the full continuum of brain injury—from disorders of consciousness to chronic care and lifelong support.
5. List the effective rehabilitation interventions utilizing functional skills that are based on a client's real-world demands.
6. Describe effective interventions across the biopsychosocial continuum to improve outcomes of pediatric brain injury
7. Evaluate key components of contemporary clinical practice guidelines and their implications for optimizing patient outcomes and functional recovery.

### Satisfactory Completion Requirement Statement

Participants must have registered and attended the entire length of the CE session. Participants must successfully complete the post-conference requisites which include session evaluation and record the anticipated changes in clinical practice as a result of participating in the program. Participants are also encouraged to participate in the 60–90-day post-activity outcomes survey which tracks the changes in practice that were implemented after participating in the CE program

### Rehabilitation Counselors



This activity has been submitted for preapproval to the Commission on Rehabilitation Counselor Certification (CRCC) for up to 18.5 contact hours.  
**CRCC Pre-approval number: 60008001330**

### Case Managers



This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 18.5 CE contact hour(s).  
Activity code: S00066292 Approval Number: 260000345

After successful participation in the program, to claim these CEs, log into your CCMC Dashboard at [www.ccmcertification.org](http://www.ccmcertification.org).

## **Social Workers**

*This program is Approved by the National Association of Social Workers (Approval # 886551225-6456) for 18.5 continuing education contact hours.*

## **Other Professionals**

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

**Learning Accommodation and Accessibility Needs:** Please notify conference staff at the time of registration for accessibility assistance.

## **Commercial Support**

No commercial support was provided for this activity.

## **How to Earn CE Credit**

### **NABIS 18<sup>th</sup> Annual Conference on Brain Injury**

Registration for the conference does not establish an account in the CE Center or automatically provide continuing education credit. You must sign into the CE Center site and evaluate the content of the activity to earn CE credit.

1. If you selected and paid for CE/CME credit, you will receive a private link to access evaluations.
2. Select the activity and on the login page, enter your e-mail address and desired password. Select "I Forgot My Password" if you need to reset the password you set up.
3. Complete, verify, or correct your demographic information and select your profession. You may select multiple professions. Click Continue.
4. Participants who have requested Psychologist CE credit, completing evaluations is optional although highly encouraged and is not tied to the issuance of CE credit.
5. Participants who have requested and consented to ASHA CEUs credit reporting must complete CE evaluations no later than March 27, 2026, to comply with ASHA policies related to reporting participants to the ASHA CE Registry. Questions about ASHA CEUs must be sent to [cds\\_support+nabis@affinityced.com](mailto:cds_support+nabis@affinityced.com)
6. Complete the activity evaluation for each session you attended and then click the attestation checkbox. When you have completed the activity evaluation, you can download your CE certificate.
7. The evaluation site will remain open to claim credit until March 27, 2026. After the evaluation period has closed, you can come back to the site at any time to download your certificate, but you will not be able to add any evaluations.

Please send any CME policy related or customer service requests to [cds\\_support+nabis@affinityced.com](mailto:cds_support+nabis@affinityced.com)